ADC Therapeutics SA (ADCT) 2023年年度报告「NYSE」.pdf

1、ADC Therapeutics SA2023 Annual ReportTable of Contents 1Table of ContentsLetter to Shareholders3Business Update8Financial Review73Report from the Auditor on the Consolidated Financial Statements85Consolidated Financial Statements for the Year Ended December 31,202389Corporate Governance129Report fro

2、m the Auditor on the Statutory Financial Statements of ADC Therapeutics SA157Statutory Financial Statements of ADC Therapeutics SA for the Year Ended December 31,2023162Report from the Auditor on the Compensation Report of ADC Therapeutics SA180Compensation Report of ADC Therapeutics SA for the Year

3、 Ended December 31,2023183Table of Contents 2DearShareholders,During 2023,we reset our business and capital allocation strategy,strengthened our team and established a clearroadmaptodrivevaluecreationforallourstakeholders.Wedidthisbyfocusingonourmostadvancedandhighest-potential clinical value driver

4、s and progressing our next generation ADC platform.At the same time,we enhancedcommercializationeffortsandreducedorganizationalcostsbyover20%toextendourexpectedcashrunwayintoQ42025,enablingfundingofthosestrategicprogramswithdatareadoutcatalystsoverthenext12months.Thisresetin2023wascriticaltoenableou

5、rstrategymovingforwardandwefirmlybelievewearewellpositionedforsuccessin2024andbeyond.EnablingourstrategyTherearetwocorepillarstoourstrategywhichweareconfidentwillunlockthetremendousvalueweseeintheCompany.Ourfirstpillar,isgroundedinourmorematureportfolio,ourhematologypipeline.Withinthis,weexpectourle

6、adasset,ZYNLONTA,will carry the Company through to profitability.We are deploying the majority of our capital to theZYNLONTA franchise to commercialize our existing 3L/3L+DLBCL indication and to pursue the substantially largerpotentialopportunityinearlierlinesofDLBCLtherapyandindolentlymphomas.Webel